Abstract
Background: To explore the therapeutic effect of Tongxinluo capsule (Tongxinluo) on patients with Syndrome X and Affective Disorder. Methods: Fifty-six patients with Syndrome X and Affective Disorder were randomly divided into a Tongxinluo capsule group and a placebo control group. The duration of treatment was 12 weeks. A 6-minute walking test, exercise load electrocardiogram and clinical symptom assessment were performed before and after treatment. After 12 weeks of treatment, the scores of the Self-Rating Anxiety Scale (SAS) and Self-Rating Depression Scale (SDS) were repeated. The levels of serum endothelin-1 (ET-1) and nitric oxide (NO) were measured before and after treatment. Results: Compared with the placebo control group, the Tongxinluo group SAS and SDS scores were lower than those before treatment (all P 0.05) when compared to before treatment. In the Tongxinluo treatment group, the levels of plasma endothelin-1 decreased significantly (P < 0.01) and nitric oxide levels were significantly increased (P < 0.01), with a significant difference when compared to the control group (P < 0.01). Conclusions: The Tongxinluo capsule can improve the Affective Disorder of Syndrome X, reduce the degree of anxiety and depression, increase exercise tolerance, reduce clinical symptoms, and improve vascular endothelial function.
Highlights
This study found that the proportion of patients with Syndrome X combined with Affective Disorder is relatively high, similar to those reported by Asbury and Vermeltfoort [3] [4]
Beta receptor blockers can partially reduce the onset of chest pain, but there is no increase in activity tolerance, and it has a risk of aggravating Affective Disorder [5]
The results (Tables 3-5) of this study suggest that patients with Syndrome X have a higher proportion of Affective Disorders, which may be associated with the higher proportion of women affected
Summary
It is accompanied by a group of syndromes with a positive electrocardiogram, a positive exercise load electrocardiogram and a normal coronary angiography, which excludes coronary artery spasm. Clinical research found that the disease was not a threat to patients’ lives, but some patients were often in a state of anxiety and depression, which affected their daily work and life. Through the progress of clinical treatment, it was found that nitrates could reduce chest pain but had no significant effect on increasing activity tolerance. Clinical and experimental results showed that the Tongxinluo capsule could improve the symptoms of dizziness in patients with cerebral infarction and relieve chest pain symptoms in patients with coronary heart disease, and according to previous studies, improve endothelial function, reduce the clinical symptoms of patients, and increase activity tolerance [6].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
